Introduction
Transforming growth factor-b (TGF-b) is a pluripotent cytokine that controls multiple cellular responses including the induction of cell growth inhibition, differentiation, cellular senescence, wound healing and apoptosis (Derynck et al., 2001; Shi and Massague, 2003; Siegel and Massague, 2003) . These cellular responses are thought to define the role of TGF-b as a tumor suppressor. Indeed, deregulated or aberrant TGF-b signaling has been strongly implicated in the pathogenesis of human solid tumors, while less is known about the role of this pathway in leukemia and lymphoma pathogenesis (Derynck et al., 2001; Shi and Massague, 2003; Siegel and Massague, 2003) .
The TGF-b pathway has been well characterized and involves TGF-b binding to the TGF-b receptor type II (TbRII), which results in the recruitment of TGF-b receptor type I (TbRI) and leads to assembly of the heterodimeric receptor complex. TbRII then phosphorylates TbRI in the 'GS sequence' located upstream from the kinase domain, and activates TbRI kinase activity (Shi and Massague, 2003) . The receptor-activated Smads (R-Smads), which are composed of Smad2 and Smad3, are then phosphorylated by TbRI. This phosphorylation releases R-Smads from the receptor complex and enables R-Smads to form a heterodimeric complex with Smad4 (Co-Smad), which then translocates into the nucleus where the TGF-b target genes are regulated (Shi and Massague, 2003) . In the nucleus, Smad proteins bind to their cognate DNA binding sites with low affinity, which greatly increases as they interact with transcriptional coactivators or transcription repressors (Shi and Massague, 2003) . Among TGF-b target genes, p21 and p15 are the best characterized. These cyclin kinase inhibitors are upregulated upon TGF-b stimulation, and mediate TGF-b growth inhibition (Derynck et al., 2001; Shi and Massague, 2003; Siegel and Massague, 2003) . In addition, TGF-binduced growth suppression can also be achieved through downregulation of the c-myc oncoprotein. Downregulation of myc expression gives rise to a positive feedback loop which further amplifies p15 and p21 expression, as c-myc is known to be a negative regulator for TGF-induced p15 and p21 expression (Derynck et al., 2001; Shi and Massague, 2003; Siegel and Massague, 2003) .
The inhibitory protein Smad7 negatively regulates TGF-b signaling by recruiting the HECT-domaincontaining E3 ubiquitin ligases Smurf1 or Smurf2 to the Smad7-TbR complex, in turn facilitating TGF-b receptor ubiquitination and subsequent degradation (Kavsak et al., 2000; Ebisawa et al., 2001) . Another inhibitory Smad, termed Smad6, antagonizes TGF-b signaling by preventing Smad2 interaction with Smad4 (Imamura et al., 1997) . The transcriptional induction of Smad6 and Smad7 by TGF-b provides a negative feedback loop to attenuate TGF-b signaling.
Apart from its role as a tumor suppressor, TGF-b can also promote tumor metastasis in the late stage of tumor development, suggesting that TGF-b serves dual roles in both tumor suppression and cancer progression (Derynck et al., 2001; Siegel and Massague, 2003) . How TGF-b regulates cancer progression and metastasis is presently not well defined. Some key proteins involved in tumor invasion and metastasis have recently been identified as targets in the TGF-b pathway, such as Snail, Slug and SIP1 (Romano and Runyan, 2000; Comijn et al., 2001; Martinez-Alvarez et al., 2004) . Snail, Slug and SIP1 are positively regulated by TGF-b and are known to mediate epithelial-mesenchymal transition (EMT), a process that can alter cell-cell adhesion, which is accompanied by the emergence of migratory and invasive properties that would therefore favor tumor invasion and metastasis (Romano and Runyan, 2000; Comijn et al., 2001; Martinez-Alvarez et al., 2004) . Further investigation is warranted to determine the physiologic relevance these proteins have in TGF-b mediated metastasis.
Early endosome pathway and the lipid-raft pathways in TGF-b signaling
The internalization of membrane bound receptors occurs mostly through the lipid-raft and clathrin endocytic pathways (Le Roy and Wrana, 2005) . It has been demonstrated that receptor endocytosis through the clathrin-endosome pathway mediates the turnover of membrane receptors, such as epidermal growth factor receptor (EGFR), leading to subsequent ablation of the receptor signal (Le Roy and Wrana, 2005) . This endocytotic pathway causes internalization of membrane receptors into the early endosome, where they are sorted and subsequently transferred to the late endosome/lysosome for degradation. Alternatively, receptors that enter into the early endosome can also be recycled to the plasma membrane for maintenance of receptor availability for ligand binding and reactivation of the receptor signal transduction. In contrast, the lipid-raft pathway is thought to play a critical role in various physiologic processes, such as protein trafficking, cell polarization and signal transduction (Le Roy and Wrana, 2005) . Numerous reports have demonstrated that the lipid-raft pathway is crucial for signal transduction in several pathways such as the T-cell receptordependent signaling cascade (Langlet et al., 2000) , B cell receptor signaling (Langlet et al., 2000) , H-ras-mediated Raf activation (Parton and Hancock, 2004) , tumor necrosis factor (TNF) receptor-mediated nuclear factor (NF)-kB activation (Legler et al., 2003) , and interferon-g (IFN-g)-induced signal transducer and activator of transcription (STAT) signaling (Sehgal et al., 2002) . Therefore, the lipid rafts represent critical sites for organizing and transmitting the extracellular signal into the cells.
TGF-b receptor internalization is also mediated through both of these critical endocytic pathways (Di Guglielmo et al., 2003; Le Roy and Wrana, 2005) . In the steady state, TGF-b receptors are partitioned into the early endosomes and lipid-raft compartments with relatively equal distribution (Di Guglielmo et al., 2003) . In contrast to EGF-mediated EGFR internalization, TGF-b does not seem to affect the partition of the receptors into these two compartments (Di Guglielmo et al., 2003) . Although the clathrin-endosome pathway traditionally plays a role in membrane receptor regulation (i.e. EGF mediated EGFR internalization), this pathway plays a crucial role in the TGF-b signaling cascade ( Figure 1a) . Intriguingly, instead of execution of receptor downregulation, the clathrin/early endosome pathway is critical for activation of TGF-b signal cascades (Di Guglielmo et al., 2003; Le Roy and Wrana, 2005) . Studies have shown that K þ depletion and a dominant-negative mutant of dynamin, which interferes with clathrin-dependent trafficking (Hayes et al., 2002) , inhibit TGF-b receptor trafficking into the early endosome antigen-1 (EEA1)-containing early endosomes and also abrogate Smad2 phosphorylation and nuclear translocation. A further study by Di Guglielmo et al. (2003) showed that TGF-b receptor type I/II (TbRI/II) were found in EEA1-containing early endosomes and Rab11-positive recycling endosomes, but not in p62-positive late endosomes, suggesting that TbRI/II localized in the early endosome is recycled back to the plasma membranes, but is not further sorted into the late endosme/lysosome for degradation. Taken together, Smad-anchor for receptor activation (SARA) was originally identified as a Smad2 interaction protein, which can also associate with the TGF-b receptor complex and present Smad2 to the receptor complexes for phosphorylation and activation (Tsukazaki et al., 1998) . Recently, it became clear as to how SARA can regulate TGF-b signaling. SARA, which contains a FYVE-domain that is responsible for the binding of SARA to phosphatidylinositol 3-phoshphate (PtdIns3P) in the membrane (Itoh et al., 2002) , is highly enriched in EEA1-containing early endosomes. It was reported that SARA may promote TGF-b receptor trafficking into the early endosome (Di Guglielmo et al., 2003; Le Roy and Wrana, 2005) , in turn leading to activation of Smad2 phosphorylation ( Figure 1a ). Another protein, hepatocyte-growth factor-regulated tyrosine-kinase substrate (HRS), which is localized in the early endosomes, can also positively regulate TGF-b signaling presumably by cooperation with SARA in recruitment of TGF-b receptor trafficking into the early endosome (Miura et al., 2000) .
Besides trafficking into the early endosomes, TGF-b receptor is also internalized into the lipid-raft compartments ( Figure 1b) . The lipid-raft pathway for TGF-b receptor internalization negatively regulates TGF signaling by inducing TGF-b receptor degradation (Di Guglielmo et al., 2003; Le Roy and Wrana, 2005) . Caveolin-1, which is highly enriched in the lipid rafts, has been shown to interact with TbRI (Razani et al., 2001) , and its overexpression leads to promotion of TGF-b receptor degradation through the lipid-raft compartment (Di Guglielmo et al., 2003; Le Roy and Wrana, 2005) . Smad7 and Smurf2, which are also present in the caveolin-1-positive vesicles (Di Guglielmo et al., 2003; Le Roy and Wrana, 2005) , may form a complex and mediate TGF-b receptor ubiquitination in this compartment (Figure 1b ), leading to its subsequent degradation by the proteasome-dependent pathway. However, the exact compartment in which the receptors are degraded has not yet been determined.
Role of cytoplasmic promyelocytic leukemia PML (cPML) in TGF-b signaling
Acute promyelocytic leukemia (APL) is associated with reciprocal translocations, which always involve the RARa locus on chromosome 17, which variably translocates and fuses to the PML, PLZF, NPM, NuMA or STAT5B genes (Pandolfi, 2001; Piazza et al., 2001) . PML gene is a member of a family of proteins, which share a novel zinc-finger binding motif termed RING and one or two additional Cys/His rich regions (B-Boxes) followed by a predicted coiled-coil domain (Zhong et al., 2000; Salomoni and Pandolfi, 2002) . The RING and B-Boxes are located at the PML N-terminal end, followed by an a-helical domain, and a coiled-coil region, at its C-terminal end, a serine/prolinerich region where PML is phosphorylated (Zhong et al., 2000; Salomoni and Pandolfi, 2002) . The RING finger, B-boxes and coiled-coil domains are retained in all PML isoforms so far identified (Jensen et al., 2001) . Although the PML RING domain can mediate protein-protein interactions, no clear biochemical function has yet been attributed to this moiety, which in other proteins is known to mediate ubiquitination (Pickart, 2001) . Moreover, whether PML displays DNA-binding ability remains unclear. The PML coiled-coil region has been shown to be responsible for the formation of stable PML homodimers (Zhong et al., 2000; Salomoni and Pandolfi, 2002) .
PML modulates the activity of key tumor suppressive pathways (e.g. p53 and Rb) (Zhong et al., 2000; Salomoni and Pandolfi, 2002) , and has been demonstrated to regulate important tumor suppressive functions: (i) cell cycle control and growth inhibition; (ii) a proapoptotic role upon a number of stimuli; (iii) induction of premature cellular senescence upon oncogenic Ras (Salomoni and Pandolfi, 2002) . Pml inactivation in mice results in susceptibility to cancer and accelerates leukemogenesis in PML-RARa transgenic models of APL (Wang et al., 1998; Rego et al., 2001) .
PML is found in macromolecular structures associated with the nuclear matrix variably termed nuclear bodies (NBs) or PML oncogenic domains (PODs), where PML colocalizes with a number of nuclear proteins (Zhong et al., 2000; Salomoni and Pandolfi, 2002) . The biochemical role of PML NBs remains unclear, although a number of NB proteins have been implicated in transcriptional regulation (Zhong et al., 2000) . In the t(15;17) promyelocytic cell line NB4, as well as in promyelocytes derived from APL patients or mouse models of APL, the PML NBs are disrupted and aberrant structures incorporating PML, RARa and the PML/RARa fusion protein colocalize (Zhong et al., 2000; Salomoni and Pandolfi, 2002) . Therefore, PML/ RARa has the ability to direct PML, RARa and presumably other nuclear antigens into these aberrant structures, thereby diverting them from their physiologic processes.
A number of cytoplasmic PML isoforms have been identified over the last decade (Fagioli et al., 1992; Jensen et al., 2001) ; however, their roles in cellular functions seem to have been overlooked. One study showed that a PML mutant lacking the nuclear localization signal (NLS), rendering PML cytosolic, was profoundly impaired in its ability to suppress transformation of NIH3T3 induced by neu oncogene . Another study concluded that nuclear localization of PML is required for its growth-suppressive function. In this study, a PML cytoplasmic isoform did not yield an appreciable effect on cell growth inhibition when compared with a PML nuclear isoform (Fagioli et al., 1998) . Owing to lack of any known functions for the cytoplasmic isoforms by these studies, research on PML in this decade has focused exclusively on the nuclear isoforms.
Recently, a cytosolic function of PML was identified and this function involves the regulation of TGF-b signaling Wrana, 2004, 2005; Lin et al., 2004) . In Pml À/À primary cells, TGF-b induced cell growth inhibition and cellular senescence are profoundly impaired (Lin et al., 2004) . Strikingly, restoration of a cytoplasmic PML isoform (cPML) in these cells, but not a nuclear PML isoform, fully rescues these TGF-b defects (Lin et al., 2004) , suggesting that cPML is essential for TGF-b functions. Further analysis of TGF-b signaling revealed that Smad2/3 phosphorylation and nuclear translocation are also markedly reduced in Pml À/À primary cells (Lin et al., 2004) . cPML interacts and colocalizes with Smad2/3 and SARA and may serve as an adaptor for Smad2/3 and SARA association (Lin et al., 2004) . As previously mentioned, TGF-b receptor internalization through the clathrin/ early endosome pathway is critical for transmitting TGF-b signal transduction. Immunofluorescence studies and sucrose flotation assays revealed that cPML is localized in the early endosome and that TbRI/II and SARA trafficking into the early endosome was remarkably reduced in Pml À/À primary cells (Lin et al., 2004) . These results point to the critical role of cPML in the regulation of TGF-b signaling through affecting the internalization of the TbRI/II/SARA/Smad2/3 complex into the early endosome. On the basis of these findings, we propose a model to explain how cPML may regulate TGF-b signaling (Figure 1a ): cPML may promote the trafficking of the TbRI/II/SARA/Smad2/3 complex into the early endosome; alternatively, cPML may be essential to retain the TbRI/II/SARA/Smad2/3 complex in the early endosome.
Role of TGF-b signaling in the hematopoietic stem cells (HSCs)/progenitors
HSC and their progenitors orchestrate hematopoiesis, a process that involves self-renewal, proliferation and differentiation (Jordan and Guzman, 2004; Warner et al., 2004) . Aberrant regulation of hematopoiesis can give rise to hematopoietic diseases and leukemia (Jordan and Guzman, 2004; Warner et al., 2004) . HSCs possess two properties: a cell renewal function that can generate daughter cells with identical functions as the parent cells and the ability to differentiate into progenitor cells, which can further differentiate to more mature cells, thereby establishing a hierarchy of the hematopoietic system (Jordan and Guzman, 2004; Warner et al., 2004) . While in vitro studies have shown that TGF-b primarily exerts an inhibitory role during hematopoiesis, the in vivo role of TGF-b in this process is still under debate (Fortunel et al., 2000) . A myriad of studies using in vitro models for hematopoietic differentiation have shown that TGF-b is able to suppress cell growth and colony formation of early progenitors (Fortunel et al., 2000) . TGF-b maintains HSC/progenitors in a quiescent state, whereas the lineage-restricted progenitors are generally less sensitive to its cytostatic effects (Fortunel et al., 2000) . For example, it was observed that primitive CD34 þ CD38 -cells show a high response to TGF-b growth inhibition, while more mature CD34 þ CD38 þ cells are far less sensitive (Van Ranst et al., 1996) . The cytostatic effects of TGF-b on these cells may partly depend on its ability to upregulate cell cycle inhibitors, such as p21, p15, and p57, and to downregulate c-myc (Kim and Letterio, 2003; Scandura et al., 2004) . Goey et al. (1989) examined the in vivo role of TGF-b in hematopoiesis by administering TGF-b to mice and found that TGF-b strongly inhibits proliferation of early progenitors. Taken together, these studies suggest that TGF-b can act as a negative regulator of hematopoiesis. One potential problem with these studies is that the high doses of TGF-b utilized may not occur in physiologic conditions, raising doubt about the role of TGF-b in hematopoiesis. To circumvent this problem, a hematopoietic conditional TbRI knockout mouse model was generated (Larsson et al., 2003) . Consistent with the inhibitory role of TGF-b, HSCs from TbRI-null mice showed increased proliferation when cultured in vitro (Larsson et al., 2003) . Surprisingly, TGF-b deficiency did not affect the size of the progenitor cells and showed normal differentiation and maturation of hematopoietic cells. Furthermore, transplanted TGF-b deficient HSCs have normal regenerative and self-renewal ability in vivo (Larsson et al., 2003) , arguing that disruption of TGF-b signaling in vivo is not sufficient to affect hematopoiesis. This experiment, however, does not rule out the possible involvement of TGF-b signaling in hematopoiesis.
Role of TGF-b signaling in leukemogenesis
Leukemia is generally viewed as a stem cell disease (Jordan and Guzman, 2004; Warner et al., 2004) . Like other neoplasms, leukemia arises from the clonal expansion of a single cell. Leukemic stem cells (LSCs) that preserve the properties of HSC (namely cell renewal capacity and ability to differentiate into progenitors) can be isolated from leukemia patients (Jordan and Guzman, 2004; Warner et al., 2004) . LSCs isolated from leukemia patients can be serially transplanted and engrafted into NOD/SCID mice. The resulting leukemic grafts were highly similar to the original disease, exhibiting identical blast morphology and dissemination profiles (Jordan and Guzman, 2004; Warner et al., 2004) . Thus, an improved understanding of the distinct molecular features and differences between LSCs and HSCs may lead to the development of therapies that can target LSCs directly, and hopefully improve treatment for patients with leukemia.
Disruption of TGF-b signaling, either by mutational inactivation of signaling components or by downregulation of their expression, is known to play an important role in cancer development Derynck et al., 2001) . Several TGF-b signaling components are bona fide tumor suppressors with the ability to constrain cell growth and inhibit cancer development at its early stages, and inactivation of these components (e.g. TbRII, TbRI, Smad2 and Smad4) are associated with some solid cancers such as breast, pancreatic and colon Derynck et al., 2001) .
Although TGF-b is proposed to act as a potent endogenous negative regulator of hematopoiesis (Fortunel et al., 2000 (Fortunel et al., , 2003 , its role in leukemogenesis remains largely unknown until recently. Wolfraim et al. (2004) reported that Smad3 is an important tumor suppressor in T-cell lineage acute lymphoblastic leukemia (T-cell ALL). Smad3 protein level was not detected in leukemic cells from children with T-cell ALL, despite the fact that Smad3 messenger level was normal (Wolfraim et al., 2004) . Using a Smad3 deficient mouse model, they further showed that the loss of Smad3 alone was insufficient to induce leukemia. However, when coupled with loss of the cyclin kinase inhibitor p27 kip1 , leukemia developed in Smad3-deficient mice (Wolfraim et al., 2004) . In acute myeloid leukemia (AML), there were two distinct mutations (a missense mutation and a frameshift mutation) in Smad4 that resulted in disruption of its ability to potentiate TGF-b transcriptional activity (Imai et al., 2001) . Furthermore, loss of TbRI and TbRII expression has been observed in patients with myeloid or lymphocytic leukemia (Le BousseKerdiles et al., 1996; DeCoteau et al., 1997) . The AML1-ETO and AML1-EVI-1 fusion proteins, which are involved in AML and chronic myeloid leukemia (CML), respectively, associate with Smad3, inhibiting TGF-b functions (Jakubowiak et al., 2000; Mitani, 2004) . These results clearly highlight the importance of TGF-b signaling in leukemogenesis. However, it is not likely that disruption of TGF-b signaling alone is sufficient for the development of leukemia. Support for this notion arises from the fact that the hematopoietic conditional TbRI knockout mice did not exhibit any sign of leukemia (Larsson et al., 2003) . Furthermore, Smad3-null mice, which exhibit profound defects in TGF-b signaling, also do not develop leukemia throughout their lifespan (Datto et al., 1999; Yang et al., 1999; Larsson et al., 2003) . Therefore, these studies suggest that disruption of TGF-b signaling may not play an important role in leukemia initiation, but instead may be involved in the progression of leukemia.
Disruption of TGF-b signaling in APL
In APL blasts where PML-RARa is overexpressed, TGF-b-induced cell differentiation is blocked. Remarkably, retinoid acid (RA) treatment, which induces PMLRARa degradation, resensitizes the cells to TGF-b, suggesting that the presence of PML-RARa overexpression in APL blasts may cause TGF-b resistance (Grignani et al., 1993; Testa et al., 1993 Testa et al., , 1994 . A recent study attempted to decipher the molecular mechanisms underlying this resistance and revealed a marked defect in TGF-b signaling including Smad2/3 phosphorylation and nuclear translocation, which is similar to that in Pml À/À primary cells (Lin et al., 2004) . Of note, degradation of PML-RARa by RA fully restores these TGF-b defects (Lin et al., 2004) . These results indicate that PML-RARa overexpression in APL blasts ablates the TGF-b signaling pathway. Given the fact that PMLRARa is present both in the cytosol and nucleus (Kastner et al., 1992; Lin and Pandolfi, unpublished observation) , it is plausible that PML-RARa may inhibit TGF-b signaling through direct inhibition of cPML to participate in TGF-b signaling. This hypothesis can be supported by the observation that overexpression of PML-RARa abrogated the interaction between Smad3 and cPML (Lin et al., 2004) . Furthermore, in APL blasts, the interaction of cPML with Smad2/3 is lost, and degradation of PML-RARa by RA restores this interaction (Lin et al., 2004) .
On the basis of these results, we speculate that PMLRARa may disrupt TGF-b signaling through two modes (Figure 2 ). In the cytosol, PML-RARa can sequester cPML away from the TbRI/II/SARA/Smad2/3 complex, thus preventing this complex from trafficking into the early endosome. In the nucleus, PML-RARa may also prevent nuclear PML from cooperating with Smad3/4 to activate TGF-b target genes, given the fact that the nuclear PML isoform PML4 can interact and cooperate with Smad3 to transactivate TGF-b transcriptional activity (Lin and Pandolfi, unpublished observation) .
Other signaling pathways involved in TGF-b resistance in leukemia
Previous studies have found that numerous TGF-b negative regulators are overexpressed in some subsets of (Dahl et al., 1998; Kronenwett et al., 2005) . c-Ski oncoproteins negatively regulate TGF-b signaling through their ability to interfere with the formation of the R-Smad and Smad4 complex and by recruiting transcription corepressors (N-CoR) and histone deacetylase (HDAC) (Liu et al., 2001) . The EVI-1 oncoprotein, which is highly upregulated in myeloid leukemia, was also shown to suppress TGF-b signaling by interacting with Smad3 and interfering with its function (Kurokawa et al., 1998; Mitani, 2004) . Furthermore, the AML1/ETO and AML1/EVI-1 fusion proteins, which are involved in AML and CML, respectively, associate with Smad3, resulting in blockade of TGF-b functions (Jakubowiak et al., 2000; Mitani, 2004) . In addition, the Tax protein, encoded by human T-cell lymphotropic virus type 1 (HTLV-1) and thought to be involved in leukemogenesis in adult T-cell leukemia, is a potent repressor of Smad-mediated TGF-b transcriptional activation by interaction with CBP/p300 (Mori et al., 2001; Lee et al., 2002) . The cell cycle inhibitor p15, which mediates cytostatic effects of TGF-b, is frequently silenced due to promoter hypermethylation in AML (Krug et al., 2002) . Other signaling pathways that induce Smad6/7 expression via Stat1, RAS-MAP kinase, NF-kB may potentially antagonize the TGF-b signaling during the leukemogenesis. Figure 3 summarizes the potential signals impinging on the cells to cause TGF-b resistance.
Conclusion and future directions
PML and TGF-b are tumor suppressors that exert similar biological functions including cell growth inhibition, induction of cellular senescence and apoptosis. Loss of PML expression is frequently detected in a variety of human cancers such as colon, prostate and breast (Gurrieri et al., 2004) , where TGF-b signaling is also frequently impaired Derynck et al., 2001) . Recently, we have identified cPML as a critical regulator of TGF-b signaling through regulation of TbRI/II and SARA accumulation in the early endosome, a crucial step for TGF-b signal transduction (Lin et al., 2004) . Future studies are needed to determine the detailed mechanism as to how cPML could regulate this process. For instance, as numerous studies have proposed that ubiquitin modification of proteins is critical for endocytosis of numerous membrane receptors such as EGFR (Le Roy and Wrana, 2005) , it will be of great interest to test in the future whether ubiquitination of TGF-b receptor provides a signal for triggering its internalization and whether or not cPML may affect the levels of receptor ubiquitination.
As TGF-b signaling is impaired in APL (Lin et al., 2004) , it will be of great interest to evaluate whether loss of TGF-b signaling indeed contributes to APL development. Intercrosses of TbRI null mice with transgenic mouse models of APL (e.g. PML-RARa transgenic mice) will address this question. Nevertheless, since loss of TGF-b signaling is not sufficient to cause leukemia, it is apparent that initiating oncogenic molecular events are needed to trigger leukemogenesis. In their presence, however, deregulation of TGF-b signaling could have devastating consequences. In this respect, it is important to underline that several of the fusion oncoproteins associated with the pathogenesis of hemopoietic malignancies share the ability to interfere simultaneously with multiple molecular pathways towards oncogenic transformation.
Finally, as aforementioned, TGF-b signaling serves dual roles not only in tumor suppression but also in promotion of tumor progression and metastasis. Interestingly, in leukemia patients, TGF-b expression is often highly elevated (Raza et al., 1992; Mori et al., 2000) . Given the fact that the TGF-b cytostatic effect in leukemogenesis may be impaired due to diverse mechanisms summarized in Figure 3 , upregulation of TGF-b may instead promote leukemia progression and invasion. This question can be addressed in established leukemia mouse models by blocking TGF-b function using a specific TGF-b inhibitor or inducing dominantnegative TbRII expression through an inducible promoter (i.e. Tet-on system) in the compound mutant mice, and evaluating the effect of TGF-b inhibition on leukemia progression and invasion. Answering these fundamental questions may shed new light, and allow further understanding on the physiologic role of TGF-b signaling and its role in leukemogenesis, ultimately providing novel therapeutic modalities for the treatment of leukemia.
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